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Running head: Neutrophil Elastase is a biomarker of disease progression and severity in 
bronchiectasis 
Descriptor:  10.03: Chronic Suppurative Lung Diseases 
Word count: 3459 
Scientific Knowledge on the Subject: There are no validated biomarkers of disease severity and 
progression in bronchiectasis. Studies in cystic fibrosis, and pilot studies in non-CF bronchiectasis 
suggest that neutrophil elastase is associated with more severe disease and airway bacterial 
infection. We prospectively tested the hypothesis that exacerbations and lung function decline is 
associated with increased sputum neutrophil elastase activity and the related circulating biomarker 
desmosine.  
What this study adds to the field: Neutrophil elastase was associated with clinical and radiological 
extent of disease and with lung function. During follow-up, elevated levels of sputum neutrophil 
elastase activity identified patients at higher risk of exacerbations and severe exacerbations 
requiring hospital admission over 3 years. Sputum elastase activity was also independently 
associated with lung function decline. Increased circulating desmosine was also associated with a 
higher risk of severe exacerbations. As few clinical parameters have been shown to be associated 
with bronchiectasis outcomes, sputum neutrophil elastase and circulating desmosine may be useful 
adjuncts to clinical assessment, or to patient evaluation in clinical trials.  
 
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org
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Abstract 
Rationale: Sputum neutrophil elastase and serum desmosine, a linked marker of endogenous elastin 
degradation, are possible biomarkers of disease severity and progression in bronchiectasis. This 
study aimed to determine the association of elastase activity and desmosine with exacerbations and 
lung function decline in bronchiectasis. 
Methods: This was a single-centre prospective cohort study using the TAYBRIDGE registry in Dundee, 
UK. 433 patients with HRCT-confirmed bronchiectasis provided blood samples for desmosine 
measurement and 381 provided sputum for baseline elastase activity measurements using an 
activity based immunosassay and fluorometric substrate assay. Candidate biomarkers were tested 
for their relationship with cross-sectional markers of disease severity, and with future exacerbations, 
mortality and lung function decline over 3-years. 
Results:  Elastase activity in sputum was associated with the bronchiectasis severity index 
(r=0.49,p<0.0001) and also correlated with MRC dyspnoea score (r=0.34,p<0.0001), FEV1 % predicted 
(r=-0.33,p<0.0001) and the radiological extent of bronchiectasis (r=0.29,p<0.0001). During 3-years 
follow-up, elevated sputum elastase activity was associated with a higher frequency of 
exacerbations (p<0.0001) but was not independently associated with mortality. Sputum elastase 
activity was independently associated with FEV1 decline (beta coefficient -0.139,p=0.001). Elastase 
showed good discrimination for severe exacerbations AUC 0.75 (0.72-0.79) and all-cause mortality 
AUC 0.70 (0.67-0.73) Sputum elastase activity increased at exacerbation (p=0.001) and was 
responsive to treatment with antibiotics. 
Desmosine was correlated with sputum elastase (r=0.34,p<0.0001), and was associated with risk of 
severe exacerbations HR 2.7 (1.42-5.29),p=0.003, but not lung function decline.  
Conclusions: Sputum neutrophil elastase activity is a biomarker of disease severity and future risk in 
adults with bronchiectasis.  
Word count: 250 
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Introduction 
Bronchiectasis is characterised by permanent bronchial dilatation associated with chronic 
neutrophilic airway inflammation.(1) The pathogenesis of bronchiectasis is poorly understood but 
activated neutrophils are thought to be a key component of the “vicious cycle” of lung damage.(2) 
Neutrophil elastase (NE) is a 29-kDa serine protease stored in azurophilic granules which may be 
released during degranulation, neutrophil extracellular trap (NET) formation, or cell death.(3-8) NE is 
pro-inflammatory, slows ciliary beat frequency and stimulates mucus secretion.(9,10) It  is found in 
high concentrations in the sputum of patients with neutrophilic lung diseases including 
bronchiectasis, COPD and cystic fibrosis(CF).(5-7) and it is thought that unopposed action of NE 
directly contributes to the pathogenesis and progression of these diseases. 
NE activity is inhibited by antiproteases including secretory leukoproteinase inhibitor produced by 
bronchial epithelium and by serum derived α-1 antitrypsin.(11) In addition, the presence of high 
concentrations of DNA released during NET formation inhibits elastase activity, both directly and 
indirectly by modulating the response to NE inhibitors.(12)  Epithelial derived factors such as the 
syndecan-1 also complex with elastase in the airway and reduce the inhibitory capacity of α-1 
antitrypsin.(7,12) 
Thus the activity of NE within the inflamed airway is usually controlled by a range of inhibitors.  In 
bronchiectasis, however, release of NE overwhelms anti-proteinase defence leading to detectable 
levels of NE proteolytic activity in sputum and bronchoalveolar lavage.(13-15) This can be measured 
readily using assays detecting cleavage of chromogenic or fluorogenic peptide-based substrates in 
sputum, or downstream by measuring the endogenous degradation of mature elastin through the 
quantification of the unique covalent cross-linking amino acids desmosine and isodesmosine in 
serum/plasma (circulating desmosine-cDES).(16,17)  
There are no widely accepted biomarkers of disease progression in bronchiectasis, but evidence is 
accumulating that sputum NE activity correlates with disease severity. Tsang et al showed in a study 
Page 5 of 42
  
of 30 patients that NE activity correlated strongly with 24h sputum volume, extent of bronchiectasis 
and forced expiratory volume in 1 second (FEV1).(13) In 385 patients with bronchiectasis from the 
UK, NE activity correlated with airway bacterial load, the presence of P. aeruginosa and the extent of 
radiological bronchiectasis.(14) No previous study has investigated the association of sputum NE 
activity or cDES with clinically relevant outcomes in bronchiectasis during long term follow-up. In this 
study we prospectively tested the hypothesis that elevated sputum NE activity or the related 
biomarker cDES is associated with increased frequency of exacerbations and lung function decline. 
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Methods 
This study was conducted and is reported according to Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines.(18) Patients were consecutively recruited to a 
prospective observational study (TAYBRIDGE registry) at Ninewells Hospital, Dundee, UK 2012-2015. 
The study was approved by the East of Scotland Research Ethics committee (12/ES/0059) and all 
patients gave written informed consent. Inclusion criteria were age>18 years, HRCT-confirmed 
bronchiectasis and clinical symptoms consistent with bronchiectasis. Exclusion criteria were; inability 
to give informed consent, active non-tuberculous mycobacterial infection, active allergic 
bronchopulmonary aspergillosis (ABPA), active tuberculosis, active malignancy, CF or pulmonary 
fibrosis with secondary traction bronchiectasis.  
For inclusion in the present analysis, patients were asked to provide serum and sputum samples at 
the same baseline visit when clinically stable (defined as no antibiotic treatment within the 
preceding 4 weeks, excluding prophylactic oral or inhaled antibiotics).  
 
Clinical assessement 
Full details of the clinical assessments are shown in the online supplement. The underlying cause of 
bronchiectasis was determined by standardised testing according to British Thoracic Society (BTS) 
recommendations.(19) The Bronchiectasis Severity Index (BSI) was calculated as described.(20) 
Quality of life was evaluated using the St.Georges Respiratory Questionnaire (SGRQ).(21) Chronic 
infection was defined as the isolation of pathogens on at least 2 occasions 3 months apart during the 
preceding 12 months. (22) Spirometry was performed according to ATS/ERS guidelines. (23) The 
severity of radiological bronchiectasis was evaluated using the Reiff score. (24) Exacerbations were 
defined according to BTS recommendations and severe exacerbations were defined as those 
requiring hospital admission.(19) 
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Sputum sampling and processing 
Spontaneous sputum samples were split for microbiology and inflammatory marker measurement. 
For measurement of inflammatory markers, including NE, spontaneous sputum was ultracentrifuged 
at 50,000g for 90 mins and the soluble fraction carefully removed. (14)  
 
Methods of measurement of neutrophil elastase activity and other inflammatory markers 
As previous studies have used several different methods of NE quantification, we simultaneously 
evaluated 3 methods in this study; two assays for sputum NE activity and one for cDES 
measurement. 
Active NE was measured using an Activity Based Immunoassay (ProAxsis Ltd) [ABI, ProteaseTag
®
 
Active NE Immunoassay referred to as the ABI-NE assay] in accordance with the manufacturer’s 
instructions (25,26) and a fluorogenic substrate-based kinetic assay (referred to as Kinetic-NE assay). 
Kinetic-NE employed the substrate N-Methoxysuccinyl-Ala-Ala-Pro-Val-7-amido-4-methylcoumarin 
(Sigma-Aldrich).  
Sputum samples were assayed at dilutions ranging from 5x to 2000x and assays remaining below the 
lowest limit of detection (0.016µg/ml) at 5x dilution were recorded as 0 for the purposes of analysis.  
Measurement of serum and sputum inflammatory markers (CXCL8, interleukin-1β, Tumour necrosis 
factor alpha (TNF-α) and EN-RAGE) were performed using commercially available ELISA. Prior to use, 
kits were validated for use in sputum according to the methods described by Woolhouse et al. (27)  
 
Serum desmosine measurement 
cDES was measured in serum using a validated LC-MS/MS method as previously described. (16, 17)  
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Exacerbation study 
Patients (n=26), included in the main study, attending hospital for a severe exacerbation of 
bronchiectasis were enrolled in a substudy of changes in NE during exacerbations.(19) Spontaneous 
sputum samples were collected on day 1 prior to commencement of antibiotics and following 
treatment at day 14. Patients received standardised treatment for 14-days based on their previous 
sputum microbiology.(19) These 26 patients subsequently had additional sampling 6-months post-
exacerbation to determine dynamics of NE.  
 
Statistical analysis 
Mean and standard deviation were used to display continuous normally distributed data with 
median and interquartile range for continuous non-normally distributed data, and frequencies and 
percentages for categorical data. The association of biomarkers with linear variables was performed 
using Spearman correlation, while between group differences were evaluated by ANOVA or Kruskal-
Walis test. Frequency of exacerbations and severe exacerbations were evaluated using Poisson 
regression adjusted for duration of follow-up. Time to event data (time to first exacerbation, first 
hospital admission and death) were analysed using Kaplan-Meier survival analysis and Cox 
proportional hazard regression for multivariable analyses. Discrimination for mortality and severe 
exacerbations at 3-years was analysed using the area under a receiver operator characteristic curve 
(AUC). Analysis of FEV1 decline over 3 years was performed using multiple linear regression with 
appropriateness of the linear regression modelling evaluated by examining the distribution of 
residuals.  In some analyses, patients were split into 3 groups based on low, intermediate and high 
elastase levels, with cut-offs selected using Youden’s index. Patients with missing data were 
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excluded from analysis of the specific test as outlined below. No imputation methods were used. 
Sample size was empirical based on previous studies with equivalent lengths of follow-up. (14)   
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Results 
Patient cohort 
The study included 433 patients of whom 381 patients were able to provide a sputum sample 
sufficient for measurement of NE activity. The flow of patients through the study are shown in the 
STROBE flowchart (Figure 1) 
Characteristics of the included patients are shown in Table 1. The median (IQR) age was 67 years (58-
74); 60.7% of patients were female and 45% of patients had idiopathic bronchiectasis. The median 
exacerbation frequency was 1 per year (interquartile range 0-3). The median BSI score was 6 
indicating a population with moderate-severe bronchiectasis (range 0-24).  
There were no significant differences between patients able and unable to produce sputum. 42 
patients were receiving long-term inhaled antibiotics and 129 were receiving long-term oral 
antibiotic treatments at baseline.   
 
Baseline characteristics Full cohort  Patients providing 
sputum 
N 433 381 
Age (years;  mean- SD) 67 (58-74) 67 (58-74) 
Gender (% female) 263 (60.7%) 225 (59.1%) 
Body mass index 25.0 (22.3-28.5) 25.1 (22.2-28.6) 
Smoking status 
(never/ex/current 
266(61%)/151(34.9%)/ 
16(3.7%) 
239(62.7%)/131(34.4%)
/11(2.9%) 
MRC dyspnoea score 2 (1-3) 2 (1-3) 
FEV1 Litres 1.58 (1.10-2.20) 1.58 (1.10-2.23) 
FEV1 % predicted 71.9 (50.0-91.0) 71.4 (49.4-90.9) 
FVC Litres 2.45 (1.84-3.21) 2.41 (1.85-3.19) 
FVC % predicted 83.9 (68.4-99.5) 83.2 (67.7-98.7) 
Aetiology of bronchiectasis 
- Idiopathic 
- Post-infective 
- Previous ABPA 
- Asthma 
- COPD 
 
195 (45.0%) 
84 (19.4%) 
37 (8.5%) 
15 (3.5%) 
22 (5.1%) 
 
169 (44.4%) 
78 (20.5%) 
34 (8.9%) 
14 (3.7%) 
19 (5.0%) 
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- Rheumatoid arthritis 
- Connective tissue disease 
- Inflammatory bowel disease 
- Primary Immunodeficiency 
- Previous NTM infection 
- Primary ciliary dyskinesia 
- Alpha 1 antitrypsin 
deficiency 
- Others 
21 (4.8%) 
6 (1.4%) 
11 (2.5%) 
18 (4.2%) 
7 (1.6%) 
4 (0.9%) 
2 (0.5%) 
 
11 (2.5%) 
17 (4.4%) 
4 (1.0%) 
11 (2.9%) 
17 (4.5%) 
4 (1.0%) 
3 (0.8%) 
1 (0.3%) 
 
10 (2.6%) 
Exacerbations per year 1 (0-3) 1 (0-3) 
Prior hospitalisation for severe 
exacerbations 
107 (24.7%) 101 (26.5%) 
St Georges Respiratory 
questionnaire total score 
44.3 (24.6-62.7) 46.1 (27.3-63.2) 
Bronchiectatic on CT 
Reiff Score 
3 (2-4) 
3 (2-6) 
3 (2-4) 
3 (2-6) 
Chronic colonisation* 
H. influenzae 
P. aeruginosa 
M. catarrhalis 
S. pneumoniae 
S. aureus 
Enterobacteriaceae 
236 (54.5%) 
129 (29.8%) 
63 (14.5%) 
51 (11.8%) 
25 (5.8%) 
34 (7.9%) 
39 (9.0%) 
213 (55.9%) 
116 (30.4%) 
60 (15.7%) 
49 (12.9%) 
23 (6.0%) 
30 (7.9%) 
39 (10.2%) 
Bronchiectasis severity index 
(mean 
Mild 
Moderate 
Severe 
6 (4-10) 
 
126 (29.1%) 
170 (39.3%) 
137 (31.6%) 
6 (4-11) 
 
108 (28.3%) 
144 (37.8%) 
129 (33.9%) 
Table 1. Baseline characteristics of the cohort. Data are presented as median (interquartile range) or N (%).  
*defined as isolation of a pathogenic microorganism in sputum when clinically stable on 2 occasions at least 3 
months apart in a 12 month period. Abbreviations: ABPA= allergic bronchopulmonary aspergillosis, FEV1= 
forced expiratory volume in 1 second, FVC= forced vital capacity, MRC= Medical Research Council, NTM= non-
tuberculous Mycobacteria.  
 
Sputum neutrophil elastase activity is associated with disease severity  
The ABI-NE assay detected activity above the lower limit of detection in 317 patients (83.2%) while 
the kinetic-NE assay detected active NE in 274 (71.9%) of samples. The two assay methods were 
highly correlated (Figure E1 online).   
Sputum NE activity as measured by the ABI-NE assay showed a univariate association with cross-
sectional markers of disease severity including MRC dyspnoea score (r=0.34,p<0.0001), SGRQ score 
(r=0.28,p<0.0001), absolute FEV1 (r=-0.31,p<0.0001), FEV1 % predicted (r=-0.33,p<0.0001), Reiff 
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score (r=0.29,p<0.0001), and the BSI (r=0.49,p<0.0001).  Similar results were obtained with the 
kinetic-NE assay, Figure 2, and figure E2 online. 
Both ABI-NE and kinetic-NE assays were correlated with sputum MPO activity (p<0.0001) but there 
was no correlation with sputum CXCL8, IL-1β, TNF-α or EN-RAGE (data not shown).  
There was a relationship between NE activity and airway bacterial load (at bacterial load above 10(7) 
cfu/ml- figure 3A and 3B). Patients chronically infected with P. aeruginosa, enterobacteriaceae and 
H. influenzae had increased levels of NE using both assays (p<0.0001) compared to patients without 
chronic bacterial infection.  
 
Sputum NE activity and longitudinal clinical outcomes 
In the sputum producing cohort, the mortality rate was 8.7% and 25.5% of patients experienced 
hospital admissions for severe exacerbations during follow-up. The median frequency of 
exacerbations was 1 per patient per year (IQR 0-3).  
As the ABI-NE assay was more sensitive and had stronger correlations with the majority of clinical 
outcomes for clarity we only present the results for the ABI-NE assay here. Using ROC analysis, ABI-
NE activity was associated with hospital admissions during follow-up AUC 0.75 (0.72-0.79) and 
mortality AUC 0.70 (0.67-0.73). Entering NE activity as a continuous variable, after multivariable 
adjustment including the BSI, a 1µg/ml increase in NE activity was independently associated with a 
0.5% increased risk of hospital admission (HR 1.005 95% CI 1.002-1.008,P<0.0001). No independent 
relationship with mortality was identified. Additional models are shown in table E1.  
 
 
Page 13 of 42
  
Using ROC analysis, we determined candidate clinically meaningful cut-off values of sputum NE. 132 
patients had values below the lower limit of detection (<0.016µg/ml- low NE), 143 patients had 
values between 0.016 and 20µg/ml (intermediate NE), while 106 had values >20µg/ml (high NE).  
Comparing the frequency of exacerbation between the three ABI-NE cut-offs using Poisson 
regression, patients with the highest elastase values (>20µg/ml) had a RR of 3.18 (95% CI 2.65-
3.18,p<0.0001) and patients with intermediate NE values had a rate ratio (RR) of 1.61 (95%CI 1.39-
1.86,p<0.0001) compared to the low elastase (reference) group indicating that high sputum NE 
activity was associated with a greatly increased frequency of future exacerbations. For severe 
exacerbations the corresponding values were RR 1.69 (95% CI 0.90-3.17,p=0.1) for intermediate NE 
values and 4.73 (2.67-8.33,p<0.0001) for the highest NE group- Figure 4A. Consistent with this, 
elevated NE activity was associated with a shorter time to next exacerbation (p<0.0001, Figure 4B), 
shorter time to next severe exacerbation (p<0.0001,Figure 4C) and increased all-cause mortality 
(Figure 4D,p<0.0001). An analysis of exacerbation frequency according to different severity groups 
using the BSI is shown in table E2 online. Prediction statistics are shown in table E3 online.  
FEV1 decline over 3 years was normally distributed. The mean FEV1 decline was 48.2mls per year 
(standard deviation 83.7). Across the defined 3 elastase groups, mean FEV1 decline was 35.6mls (sd 
81.1) for NE activity <0.016µg/ml, 49.5ml (sd 92.5) for intermediate elastase levels and 56.4ml (sd 
67.4) for those with NE >20µg/ml. On univariate regression there was a weak but statistically 
significant relationship between NE activity and FEV1 decline (p=0.004). After adjustment for BSI, 
gender and baseline FEV1, increasing NE-ABI elastase was associated with more rapid lung function 
decline (beta coefficient -0.139,p=0.001, model fit r=0.7). 
   
Serum desmosine is associated with age and disease severity  
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cDES was most strongly correlated with age (r=0.48,p<0.0001, Figure 5A). Additional univariate 
correlations were observed between cDES and MRC dyspnoea score (r=0.32,p<0.0001), SGRQ 
(r=0.40,p<0.0001), absolute FEV1 (r=-0.39,p<0.0001) and Reiff score (r=0.15,p=0.002). cDES was also 
significantly higher in patients colonised with P. aeruginosa (p<0.0001). There was an association 
between cDES and BSI (r=0.46,p<0.0001). Correlations were demonstrated with sputum NE activity 
(Figure E1 online). Removing the outliers at >1ng/ml showed similar correlations with markers of 
disease severity as described in the online supplement (p7).  
 
In the total cohort, mortality was 9.5% and 22.6% of patients were admitted to hospital for severe 
exacerbations. Median exacerbation frequency was 1 per patient per year (IQR 0-3).  
In analysis of longitudinal clinical outcomes, there was no relationship between cDES and FEV1 
decline over 3 years (p=0.1), but there was a strong relationship between cDES and severe 
exacerbations (HR 6.0 95%CI 3.61-10.0,p<0.0001) which persisted after adjustment for BSI  (HR 2.7 
95% CI 1.42-5.29,p=0.003). There was no significant association between cDES and moderate 
exacerbations (p=0.2), but after combining moderate and severe exacerbations a statistically 
significant association above 0.4ng/ml was observed – RR 1.96 95% CI 1.61-2.39,p<0.0001.  
There was similarly an association between cDES and all-cause mortality (HR 2.60 95% CI 1.24-
5.45,p=0.01), but this relationship was not statistically significant after adjustment for BSI (HR 1.15 
95% CI 0.45-2.91,p=0.8). Additional models are shown in table E2. The AUC values for biomarkers 
compared to individual recognised predictors of outcome in bronchiectasis is shown in table E4.  
A sensitivity analysis conducted in patients taking long term antibiotics demonstrated that sputum 
NE and cDES had similar associations with long term outcomes compared to the overall cohort (table 
E5).   
Changes in neutrophil elastase at exacerbation and after antibiotic therapy  
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To determine whether sputum NE was responsive to treatment we studied 26 patients during an 
acute exacerbation requiring intravenous antibiotic therapy. Characteristics of the patients included 
compared to the overall population are shown in table E6.  
Median ABI-NE levels were 0.39µg/ml (IQR 0-23.5) at baseline, 57.0µg/ml (3.3-145µg/ml) at onset of 
exacerbation, 0µg/ml (0-25.8) after 14 days of antibiotic therapy and 1.3µg/ml (0-29.9) at the second 
stable measurement 6 months later (Figure 6). Although NE activity was generally higher at 
exacerbations than at baseline (p=0.0002) and at recovery (p<0.0001), the assay did not discriminate 
between exacerbation and disease quiescence because of the high baseline activity in some 
individuals. The ABI-NE assay level >50µg/ml was associated with a sensitivity of 57.7% and 
specificity of 92.3%. An increase from baseline was present at exacerbation in 20/26 patients at 
exacerbation.  
Remarkably, even with this small sample size, failure to return to NE baseline levels after completion 
of antibiotics was associated with a shorter time to the next exacerbation (HR 2.92, 95% CI 1.16-
7.38,p=0.02). Data on the correlation between elastase measurements at two stable visits > 
6months apart are shown in Figure E3 online. 
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Discussion 
This study indicates a role for sputum NE activity as a biomarker of disease severity and disease 
progression in bronchiectasis, while also providing the first data on the linked biomarker cDES. NE 
activity in sputum was independently associated with risk of exacerbations, severe exacerbations 
and lung function decline, even after adjustment for underlying severity of the disease. This suggests 
NE is a useful marker that may identify patients at future risk. Elastase is dynamic, responding to 
treatment and we show that a failure to improve elastase with treatment predicts a shorter time to 
next exacerbation. To the best of our knowledge, NE activity is the first biomarker to be associated 
with this range of clinically relevant outcomes in bronchiectasis. This confirms and extends previous 
observations in diverse bronchiectasis populations in Hong Kong, Belgium and the UK. (13-15) 
Tsang et al previously showed that 24h NE output correlated with 24h sputum volume, radiological 
severity of bronchiectasis and FEV1.(13) NE is not the only airway protease found in the 
bronchiectasis lung, but Goeminne et al in a study of 63 patients, showed that NE accounted for 82% 
of the total gelatinolytic activity of sputum, making a greater contribution than matrix 
metalloproteinases.(15) Goeminne et al also showed a statistically significant association between 
NE and FEV1% predicted, which was not seen for MMP-9.(15) In the largest previous study on 385 
patients with bronchiectasis, sputum NE activity measured using a kinetic assay was found to be 
associated with bacterial load, P. aeruginosa infection, radiological severity and lung function.(14) 
Previous studies, however, have used a variety of different assays, and a limited number of 
bronchiectasis severity indices without longitudinal follow-up.  
It is essential that candidate biomarkers undergo independent validation because markers typically 
perform better in their “discovery” or derivation cohort than in subsequent independent 
cohorts.(28) Our study therefore validates these previous findings in a large cohort, as we 
demonstrate a clear association between elastase activity and a variety of markers of disease 
severity including breathlessness, quality of life and FEV1. There was a strong relationship between 
elastase activity and the multidimensional BSI.(20) 
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We observed strong relationships between NE activity and bacterial load. NE activity was also 
highest in patients with P. aeruginosa infection and this is consistent with previous studies in 
bronchiectasis which have shown that bacteria, and P. aeruginosa in particular, are the key drivers of 
airway neutrophilic inflammation (22), and that that P. aeruginosa infection represents a distinct 
clinical phenotype associated with earlier mortality, more frequent exacerbations and worse quality 
of life.(14, 22, 29, 30)  
While a biomarker that identifies patients with more severe disease is of interest, it is most 
important to find biomarkers that can identify patients at highest risk of future exacerbations and 
disease progression. Our study shows that NE activity is independently associated with lung function 
decline over 3 years, identifying elastase as the first biomarker that is associated with disease 
progression in bronchiectasis. In addition, elastase was an independently associated with future 
exacerbations. Although patients with the highest elastase levels were at an increased risk of early 
death, this association was not independent of disease severity using the BSI, and only the highest 
levels of elastase were associated with increased mortality, indicating that airway inflammation itself 
was not likely to be the primary driver of mortality in this population. 
Our data are consistent with those seen in CF, where neutrophil elastase has been shown to be a key 
biomarker.(31-33) In a pooled analysis of 4 multicentre studies Mayer-Hamblett et al, showed a clear 
relationship between elastase and FEV1.(31) Sagel et al extended these observations demonstrating 
that elastase was the strongest predictor of lung function decline over 3 years.(32) Sly also 
demonstrated that elastase activity present in BAL was the strongest predictor of the early 
development of bronchiectasis in infants with CF.(33)  
Bronchiectasis has been a neglected disease and so, in contrast, biomarker studies are in their 
infancy. Markers identified in bronchiectasis include sputum MMP-8 and MMP-9 which were shown 
in a Chinese cohort to correlate with radiological severity, FEV1 and the BSI. (34) These findings were 
extended by Taylor et al, who showed that MMP-8 and MMP-9 were higher with P. aeruginosa or H. 
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influenzae colonisation and inversely associated with lung function.(34,35) These studies included 
102 and 86 patients respectively and included only 1 year of follow-up, therefore further large 
validation studies are required.  
Inconsistent results were seen with cytokines such as CXCL8, TNF-α and IL-1β in previous studies and 
in the present study these were not significantly associated with clinical outcomes.(14, 36) 
No blood biomarkers have been studied in detail in bronchiectasis which makes the identification of 
cDES as a potential marker of severity of significant interest. The results here are similar to those 
recently described in a large COPD cohort where cDES was associated with age and quality of life. 
(17)  
There is overwhelming evidence that elastase is involved in the pathophysiology of bronchiectasis. 
Destruction of elastin, basement membrane collagen and proteoglycans by proteases contributes to 
disease progression and may explain the relationship between elastase and FEV1 decline observed in 
this study.(37)
 
NE induces neutrophil dysfunction through multiple mechanisms including cleavage of 
FcγRIIIb, and has also been shown to cleave complement receptor 1 in patients with CF.(3, 38) NE 
can also cleave the opsonin iC3b from the surface of pathogens, leading to opsonin/receptor 
mismatch(39) while Vandivier et al showed that elastase cleaved phosphatidylserine, preventing the 
phagocytosis and clearance of apoptotic cells. (40) Not surprisingly therefore, therapeutic 
manipulation of elastase has been proposed in bronchiectasis. In a proof of concept study, Stockley 
et al tested an oral NE inhibitor for 4 weeks in 38 patients with bronchiectasis. (41) Although the 
primary outcome of a reduction in sputum neutrophils was not achieved, the study showed a 
clinically important and significant improvement in FEV1 of 100ml vs placebo, and a greater than 4-
point improvement in the SGRQ which did not reach statistical significance.(41)  
While NE activity appears able to stratify patients as high and low risk of disease progression, we 
cannot currently recommend management decisions based on elastase measurement. The next step 
would be implementation of such a strategy in a controlled clinical trial. Sputum biomarkers are not 
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currently in routine use, and implementation would be greatly enhanced by the availability of a 
point of care device that could make the assay more rapid and accessible.  
As we and others have shown that elastase is responsive to change and that changes in elastase 
correlate with clinical outcomes, measurement of NE may be particularly useful in clinical trials, 
where it could be used as an early “signal searching” or “early efficacy” end-point for new antibiotics 
or anti-inflammatory therapies.(14, 42) Such end-points are essential to identify candidates in 
smaller clinical trials before embarking on large definitive phase-3 studies. It has been suggested 
that the absence of such an early response end-point has contributed to the failure of a number of 
large phase-3 programmes to reach their primary end-points.(43) NE should be further evaluated for 
this purpose.  
There are a wide range of NE assays commercially available and our data only demonstrate the 
validity of the ABI-NE, kinetic NE and cDES assays in bronchiectasis. Additional studies with 
alternative assays including those quantifying total elastase rather than elastase activity and urinary 
desmosine may not give the same results. This study is single centre, although the external validity 
of our results are strengthened by the similarity of the characteristics of these patients with other 
cohorts across Europe and the previous validation of findings from our centre across multiple 
European centres. (20, 44) We did not obtain multiple elastase measurements over time except in a 
subset and it will be important in future to determine if repeated measurement of elastase could 
provide improved predictive accuracy. The cut-offs that we proposed here for intermediate and high 
levels of NE have not been independently validated and should be tested in future cohort studies. 
The use of expectorated sputum for NE measurement may introduce sampling bias because only 
patients able to produce sputum could be included.  
 
Conclusion 
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Sputum NE activity is associated with the future risk of exacerbations, including severe 
exacerbations and lung function decline in bronchiectasis. Elastase is therefore a marker of disease 
progression in bronchiectasis that may complement clinical assessment of multidimensional clinical 
scoring systems. NE levels reflect clinical status, and its response is associated with future risk of 
exacerbations. Future interventional studies should therefore evaluate whether elastase reduction 
can be used as a surrogate of efficacy in clinical trials. 
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Figure legends 
 
Figure 1. STROBE flow chart of study inclusion and exclusions. Abbreviations: NTM= non-tuberculous 
mycobacteria, ABPA= allergic bronchopulmonary aspergillosis, Bx= bronchiectasis, CT= computed 
tomography, ABI-NE= Activity based immunoassay for neutrophil elastase. Patients with elastase 
levels below the lower limit of detection “not detected” were included in the analysis with values 
treated as zero.  
 
Figure 2. Association between neutrophil elastase and severity of disease. The ABI-NE assay (upper 
panels) and kinetic NE assay (lower panels) are significantly different between bronchiectasis 
severity index and FEV1 % predicted groups and correlate with the SGRQ. NS= no significant 
difference compared to FEV1 >80% predicted. *p<0.05 compared to >80% predicted FEV1 
***p<0.0001 compared to >80% FEV1 % predicted. Across group comparisons for FEV1 p<0.0001 by 
Kruskal-Walis test. BSI and FEV1 cut-offs were chosen as those used in (20) Error bars show median 
with interquartile range.   
 
Figure 3. Association between neutrophil elastase and sputum bacterial load. Figure 3A shows data 
for the ABI-NE assay, 3B shows the Kinetic assay. ***p<0.0001 compared to no organism isolated. 
Figures show median with the upper error bar showing the upper limit of the interquartile range.  
 
Figure 4. Association between neutrophil elastase and longitudinal clinical outcomes. Figure 4A Odds 
ratios from Poisson regression, elastase level >0.016µg/ml are associated with significantly increased 
risk of moderate exacerbations (p<0.0001) and levels >20µg/ml are associated with increased severe 
exacerbations (p<0.0001). B: Elevated neutrophil elastase is associated with shorter time to next 
exacerbation (p<0.0001 by Log rank test), C: Time to next hospitalisation for severe exacerbation 
over 36 months (p<0.0001 by log rank test), D: All-cause mortality over 3 years (p<0.0001 by log rank 
test, comparison between <0.016µg/ml vs 0.016-20µg/ml= NS). <0.016µg/ml, n=132, 0.016 µg/ml-20 
µg/ml,n=143 and >20 µg/ml, n=106 patients. 
 
Figure 5. Spearman rank correlation analysis of the relationship between serum total desmosine and 
age, bronchiectasis severity index (BSI), SGRQ and FEV1 % predicted.   
 
Figure 6. Changes in sputum NE activity at exacerbation and recovery. 
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Figure 1. STROBE flow chart of study inclusion and exclusions. Abbreviations: NTM= non-tuberculous 
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Figure 2. Association between neutrophil elastase and severity of disease. The ABI-NE assay (upper panels) 
and kinetic NE assay (lower panels) are significantly different between bronchiectasis severity index and 
FEV1 % predicted groups and correlate with the SGRQ. NS= no significant difference compared to FEV1 
>80% predicted. *p<0.05 compared to >80% predicted FEV1 ***p<0.0001 compared to >80% FEV1 % 
predicted. Across group comparisons for FEV1 p<0.0001 by Kruskal-Walis test. BSI and FEV1 cut-offs were 
chosen as those used in (20) Error bars show median with interquartile range.    
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Figure 3. Association between neutrophil elastase and sputum bacterial load. Figure 3A shows data for the 
ABI-NE assay, 3B shows the Kinetic assay. ***p<0.0001 compared to no organism isolated. Figures show 
median with the upper error bar showing the upper limit of the interquartile range.  
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Figure 4. Association between neutrophil elastase and longitudinal clinical outcomes. Figure 4A Odds ratios 
from Poisson regression, elastase level >0.016µg/ml are associated with significantly increased risk of 
moderate exacerbations (p<0.0001) and levels >20µg/ml are associated with increased severe 
exacerbations (p<0.0001). B: Elevated neutrophil elastase is associated with shorter time to next 
exacerbation (p<0.0001 by Log rank test), C: Time to next hospitalisation for severe exacerbation over 36 
months (p<0.0001 by log rank test), D: All-cause mortality over 3 years (p<0.0001 by log rank test, 
comparison between <0.016µg/ml vs 0.016-20µg/ml= NS). <0.016µg/ml, n=132, 0.016 µg/ml-20 
µg/ml,n=143 and >20 µg/ml, n=106 patients.  
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Figure 5. Spearman rank correlation analysis of the relationship between serum total desmosine and age, 
bronchiectasis severity index (BSI), SGRQ and FEV1 % predicted.    
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Figure 6. Changes in sputum NE activity at exacerbation and recovery.  
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Supplementary Methods 
Clinical assessments 
Patients were managed at a specialist bronchiectasis clinic and received investigations and 
management in line with the recommendations of the British Thoracic Society (BTS) bronchiectasis 
guidelines.(19) Aetiology was determined by standardised testing according to BTS 
recommendations and performed in all patients through a standardised computer “order set”. (19) 
The bronchiectasis severity index was calculated as previously described. (20) Sputum was sent for 
standard qualitative and quantitative microbiology. (14) The study was initiated prior to the 
published validation of the Quality of Life Bronchiectasis Questionnaire and so quality of life was 
evaluated using the St. Georges Respiratory Questionnaire (SGRQ), the most widely used quality of 
life tool in bronchiectasis research at that time. (21) Cough was measured with the Leicester cough 
questionnaire. Breathlessness was quantified by the MRC dyspnoea score. Chronic colonisation was 
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defined as the isolation of pathogens on at least 2 occasions 3 months apart during the preceding 12 
months. (22) The predominant pathogen is defined as the organism isolated most frequently during 
the study period. Spirometry was performed according to ERS guidelines. (23) The severity of 
radiological bronchiectasis was evaluated using the Reiff score, which is a simple classification 
system that grades the degree of dilatation per lobe (considering the Lingula as a separate lobe) and 
awards points as follows 1=tubular/cylindrical bronchiectasis 2= varicose bronchiectasis 3= cystic 
bronchiectasis. (24) The maximum score is 18 points.  
Patient data was linked using a unique identifier to electronic medical records systems available in 
the East of Scotland allowing documentation of all antibiotic prescriptions, hospital admissions and 
all-cause mortality. This was used to validate investigator recorded data. In the case of 
exacerbations, primary care prescriptions were used to confirm self-reported exacerbations.  
 
 
Comparison of methods for quantification of neutrophil elastase activity in bronchiectasis 
The ProteaseTag® Active NE activity-dependent immunoassay (ProAxsis Ltd.) was carried out 
according to the manufacturer’s instructions (http://proaxsis.com/products_list/neutrophil-
elastase).  Briefly, active NE activity is selectively captured from the sample using a specific NE-Tag 
and the subsequent antibody step provides additional signal amplification with increased sensitivity.  
The kinetic assay was conducted using the fluorogenic substrate, N-Methoxysuccinyl-Ala-Ala-Pro-
Val-7-amido-4-methylcoumarin (Sigma-Aldrich) at a final concentration of 50 µM in 50 mM Tris/HCl 
buffer, pH 7.7 containing 0.1 M NaCl and hydrolysis monitored using an Optima FluoStar (BMG 
Labtech, Germany) at excitation 380 nm and emission 460 nm. In each case, a calibration curve was 
constructed using active native NE (Merck Millipore). Neutrophil elastase data were non-normally 
distributed and so data are presented as median with interquartile range (IQR). Across all patients, 
the ABI-NE assay found a median of 1.67µg/ml (IQR 0-23.9) while the kinetic NE assay showed a 
median of 1.25 µg/ml (0-18.7). 
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The NE-ABI detected neutrophil elastase activity above the lower limit of detection in 317 patients 
(83.2%) while the kinetic assay detected active NE in 274 (71.9%) of samples. The two assay methods 
were highly correlated (Figure E1A) but NE-ABI showed superior sensitivity identifying active NE in 
44 samples where it was undetectable with the kinetic assay. Conversely there was 1 sample where 
active NE was detected by the kinetic assay where it was undetectable with the NE-ABI. The Bland-
Altman plot showed good agreement between the two sputum NE assay methods.  
Median serum desmosine levels were 0.28ng/ml (IQR 0.21-0.36). There was a significant correlation 
between serum desmosine level and NE-ABI (Figure E1C) and also the kinetic-NE assay (Figure E1D)  
 
Statistical analysis- supplementary information 
Mean and standard deviation were used to display continuous normally distributed data with 
median and interquartile range for continuous non-normally distributed data, and frequencies and 
percentages for categorical data. Distribution was evaluated with the D’Agostino-Pearson Omnibus 
test unless otherwise indicated. The association of biomarkers with linear variables e.g other assays 
and quality of life, was performed using Spearman correlation which does not assume a normal 
distribution and assesses the strength and direction of a monotonic relationship whether linear or 
not. For data organised into groups, such as the mild, moderate and severe categories of the 
bronchiectasis severity index or the established cut-offs for FEV1, between group differences were 
evaluated by ANOVA or Kruskal Wallis test according to the distribution of the data. Frequency of 
exacerbations and severe exacerbations were evaluated using Poisson regression adjusted for 
duration of follow-up. Time to event data (time to first exacerbation, first hospital admission and 
death) were analysed using Kaplan-Meier survival analysis for unadjusted data and Cox proportional 
hazard regression for multivariable analyses. Time zero for these analyses was the date of elastase 
or desmosine measurement as appropriate with follow-up until death, censor (loss to follow-up) or 
end of study at 3 years. For the analysis of time to next exacerbation in the exacerbation subcohort, 
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time zero was day 14 post exacerbation. Discrimination for mortality and severe exacerbations at 3 
years was analysed using the area under a receiver operator characteristic curve (AUC). For these 
analyses, a fixed time point of 3 years was used. Analysis of FEV1 decline over 3 years follow-up was 
performed using multivariable linear regression with appropriateness of the linear regression 
modelling evaluated by examining the distribution of residuals.  In some analyses, patients were split 
into 3 groups based on low, intermediate and high elastase levels. Cut-offs were determined by 
analysis of the receiver operator characteristic curves with candidate cut-offs selected using 
Youden’s index. Patients with missing data were excluded from analysis of the specific test as 
outlined below. No imputation methods were used. Missing follow-up data was minimised through 
the use of electronic data. Sample size was empirical based on previous studies with equivalent 
lengths of follow-up. (14)   
Analyses were conducted using SPSS Version 21 for Windows (SPSS, Chicago, Illinois, USA) and Graph 
Pad Prism Version 6 (Graph Pad Software, Inc. San Diego, California, USA).  
 
Supplementary Results, Figures and Tables 
Supplementary data are presented in the order in which they appear in the text.  
Comparison between different methods for evaluating sputum elastase activity and serum 
desmosine.  
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 Figure E1. Comparison of 3 methods for quantification of neutrophil elastase activity in BE. A: 
comparison of two methods of quantifying sputum neutrophil elastase activity by linear regression, 
B: Bland-Altman comparison between the two methods of sputum neutrophil elastase quantification 
C: Correlation between activity based immunoassay for neutrophil elastase (ABI-NE) and serum total 
desmosine. D: correlation between activity determined by kinetic-NE assay and serum total 
desmosine.  
 
 
Relationship between sputum neutrophil elastase activity and disease severity and activity using 
the kinetic assay 
Using the kinetic elastase activity assay, there were statistically significant relationships between 
elastase and MRC dyspnoea score (r=0.33,p<0.0001), Leicester cough questionnaire (r=-
0.23,p<0.0001), SGRQ (r=0.27,p<0.0001), absolute FEV1 (r=-0.30,p<0.0001), FEV1 % predicted, (r=-
0.33,p<0.0001), Reiff score (r=0.29,p<0.0001), and BSI (r=0.48,p<0.0001).  
 
Both assays were strongly associated with sputum colour using the Murray chart as shown in figure 
E2 below.  
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 Figure E2. Relationship between NE activity using two different assays and sputum colour. 
Comparisons across the groups are statistically significant p<0.0001 by Kruskal-Walis test for both 
assays. Sputum colour was assessed using the Chart of Murray et al (ERJ 2011).  
 
 
Table E1. Additional models evaluating the association between NE activity and mortality or 
hospital admissions 
 
Assay and 
model 
Mortality Hospital admissions 
ABI-NE 
Unadjusted 
Model 1 
Model 2 
Model 3 
 
1.04 (1.00-1.07),p=0.04 
1.04 (1.00-1.08),p=0.04 
1.00 (0.92-1.03),p=0.5 
1.00 (0.92-1.03),p=0.4 
 
1.09 (1.07-1.11),p<0.0001 
1.09 (1.07-1.11),p<0.0001 
1.05 (1.02-1.08),p<0.0001 
1.05 (1.02-1.08),p=0.001 
Kinetic NE 
Unadjusted 
Model 1 
Model 2 
 
1.04 (1.02-1.06),p<0.0001 
1.03 (1.01-1.05),p=0.003 
1.01 (0.98-1.03),0.5 
 
1.03 (1.02-1.05),p<0.0001 
1.03 (1.01-1.05),p<0.0001 
1.01 (0.99-1.02),p=0.1 
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Model 3 1.01 (0.97-1.03),p=0.9 1.01 (0.99-1.02),p=0.1 
Desmosine 
Unadjusted 
Model 1 
Model 2 
Model 3 
 
2.60 (1.24-5.45),p=0.01 
2.35 (0.90-6.17),p=0.08 
1.15 (0.45-2.91),p=0.8 
10.5 (0.29-3.94),p=0.9 
 
6.0 (3.61-10.0),p<0.0001 
5.73 (3.37-9.76),p<0.001 
2.7 (1.42-5.29),p=0.003 
1.80 (0.90-3.59),p=0.1 
Table E1. Summary of multivariable models.  Model 1- adjusted for age and gender only, model 2- 
adjusted for BSI which incorporates age, MRC dyspnoea score, exacerbation frequency, prior 
hospitalisation, radiological severity, bacterial colonisation, P. aeruginosa status and BMI. Model 3- 
adjusted for age, gender, MRC dyspnoea score, exacerbation frequency, prior hospitalisation, 
radiological severity and P. aeruginosa as independent variables.  
 
Table E2- Prediction of exacerbations independent of the Bronchiectasis severity index 
Moderate and severe 
exacerbations 
Low elastase group Intermediate elastase group High elastase group 
BSI low risk 
BSI intermediate risk 
BSI high risk 
1.0 (reference) 
 
1.0 (reference) 
1.0 (reference) 
1.42 (0.56-3.61),p=0.5 
1.78 (0.91-3.46),p=0.09 
1.81 (1.36-2.41),p<0.0001 
1.62 (1.08-2.45),p=0.02 
1.84 (1.01-3.32),p=0.04 
2.00 (1.53-2.63),p<0.0001 
Moderate 
exacerbations 
Low elastase group Intermediate elastase group High elastase group 
BSI low risk 
BSI intermediate risk 
BSI high risk 
1.0 (reference) 
 
1.0 (reference) 
1.0 (reference 
1.46 (0.57-3.71),p=0.4 
1.84 (0.95-3.58),p=0.07 
1.80 (1.27-2.55),p=0.001 
1.67 (1.10-2.52),p=0.02 
1.87 (1.03-3.37),p=0.04 
1.87 (1.34-2.60),p<0.0001 
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Table E2. Poisson regression analysis of different elastase groups demonstrating the independent 
predictive value of sputum elastase activity for exacerbations adjusted for the Bronchiectasis 
severity index.  
 
Table E3- Predictive indices for NE activity and mortality or severe exacerbations 
Table E3. Predictive indices of NE cut-offs to predict mortality and hospital admissions for severe 
exacerbations. 
 
 
Sensitivity analysis of desmosine without outliers 
It was noted that 4 data points with circulating desmosine >1ng/ml were outliers that could have a 
significant impact on correlations with markers of disease severity. After excluding these outliers 
correlations were as follows: MRC dyspnoea score (r=0.31,p<0.0001), age (r=0.37,p<0.0001), LCQ 
(r=-0.20,p=0.0002), SGRQ (r=0.39,p<0.0001), absolute FEV1 (r=-0.38,p<0.0001, FEV1 % predicted (r=-
0.26,p<0.0001) and reiff score (r=0.14,p=0.003).  
Table 4 shows the AUC values for mortality and hospital admissions relative to recognised predictors 
of poor outcome in BE.  
Organisms PLR NLR Sensitivity Specificity PPV NPV 
Mortality       
       ABI NE >20 µg/ml 2.2 (1.5-3.1) 0.6 (0.4-0.9) 54.6% (36.4-71.9%) 74.7% (69.8-79.2%) 17.0% (10.4-25.5%) 94.6% (91.2-96.9%) 
ABI NE <0.016µg/ml 1.2 (1.0-1.5) 0.6 (0.3-1.2) 78.8% (61.1-91.0%) 35.9% (30.9-41.2%) 10.4 (6.9-14.9%) 94.7% (89.4-97.8%) 
Severe exacerbations       
        ABI NE >20 µg/ml 3.2 (2.3-4.3) 0.5 (0.4-0.7) 56.7% (46.3-66.7%) 82.0% (77.1-86.3%) 51.9% (42.0-61.7%) 84.7% (80-88.8%) 
ABI NE <0.016µg/ml 1.4 (1.3-1.6) 0.4 (0.2-0.6) 84.5% (75.8-91.1%) 41.2% (35.4-47.2%) 32.9% (27.1-39.2%) 88.6% (81.9-93.5%) 
Mortality       
  Kinetic NE >20 µg/ml 1.9 (1.2-2.9) 0.7 (0.6-1.0) 42.4% (25.5-60.8%) 77.6% (72.8-81.9%) 15.2% (8.6-24.2%) 93.4% (89.9-96.0%) 
Kinetic NE <0.016µg/ml 1.4 (1.1-1.8) 0.6 (0.3-1.0) 72.7% (54.5-86.7%) 48.3% (42.9-53.7%) 11.8% (7.7-17.0%) 94.9% (90.6-97.7%) 
Severe exacerbations       
  Kinetic NE >20 µg/ml 2.6 (1.8-3.6) 0.7 (0.6-0.8) 44.3% (34.2-54.8%) 82.8% (77.8-86.9%) 46.7% (36.3-57.4%) 81.3% (76.3-85.6%) 
Kinetic NE <0.016µg/ml 1.9 (1.6-2.2) 0.3 (0.2-0.5) 81.4% (72.3-88.6%) 56.0% (50.0-61.9%) 38.7% (32.0-45.8%) 89.8% (84.4-93.9%) 
Page 38 of 42
 Mortality prediction Hospital admissions 
ABI-NE 0.70 (0.67-0.73) 0.75 (0.72-0.79) 
Kinetic-NE 0.66 (0.56-0.76) 0.74 (0.68-0.80) 
Desmosine 0.72 (0.65-0.79) 0.65 (0.59-0.71) 
Age 0.75 (0.67-0.83) 0.51 (0.45-0.58) 
FEV1 0.72 (0.64-0.81) 0.72 (0.66-0.78) 
Exacerbation freq. 0.67 (0.57-0.76) 0.79 (0.74-0.85) 
MRC dyspnoea score 0.66 (0.56-0.75) 0.79 (0.74-0.84) 
P. aeruginosa 0.56 (0.46-0.66) 0.72 (0.65-0.79) 
Lobes involved on CT 0.60 (0.52-0.68) 0.66 (0.61-0.72) 
BSI score 0.78 (0.70-0.84) 0.89 (0.85-0.93) 
Table E4. Comparison of different individual clinical predictors of outcome in bronchiectasis. 
Abbreviations BMI= body mass index, FEV1= forced expiratory volume in 1 second, BSI= 
bronchiectasis severity index.  
 
Table E5. Sensitivity analysis in patients using long term antibiotic treatments  
Assay Mortality (HR) Hospitalisation (HR) 
Long term 
antibiotic users 
ABI-NE 
Kinetic-NE 
Desmosine 
Long term oral 
antibiotics only 
ABI-NE 
Kinetic-NE 
Desmosine 
Long term inhaled 
antibiotics 
ABI-NE 
Kinetic-NE 
Desmosine 
 
 
1.02 (0.98-1.06),p=0.3 
1.04 (1.01-1.06),p=0.003 
1.91 (0.65-5.56),p=0.2 
 
 
1.02 (0.96-1.09),p=0.5 
1.03 (0.99-1.08),p=0.1 
1.79 (0.44-7.25),p=0.4 
 
 
1.36 (1.12-1.62),p=0.004 
1.03 (1.00-1.06),p=0.03 
21.7 (0.40-1246.2),p=0.8 
 
 
1.06 (1.04-1.09),p<0.0001 
1.02 (1.00-1.04),p=0.01 
3.72 (1.86-7.44),p<0.0001 
 
 
1.09 (0.98-1.20),p=0.1 
1.02 (0.99-1.05),p=0.2 
3.59 (1.68-7.65),p=0.001 
 
 
1.16 (1.06-1.27),p=0.001 
1.02 (1.00-1.04),p=0.04 
4.03 (1.49-10.91),p=0.006 
Table E5. Association of biomarkers with clinical outcomes in patients receiving long term antibiotic 
treatments.   
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We also studied the association with exacerbations in these groups. In patients receiving long term 
inhaled antibiotics we observed a RR 3.18 (2.65-3.83),p<0.0001 for the highest elastase group and 
1.61 (1.39-1.86),p<0.0001 for the intermediate elastase levels compared to the low elastase group 
(reference). In patients receiving oral antibiotics only, the corresponding values were 1.47 (1.11-
1.95),p=0.007 and 1.28 (1.02-1.60),p=0.03 respectively. For patients receiving any long term 
antibiotic the effect was 2.04 (1.57-2.65),p<0.0001 and 1.36 (1.12-1.63),p=0.002 respectively 
compared to the reference group (NE <0.016ug/ml). 
 
Table E6. Characteristics of patients in the exacerbation substudy 
The patients included in the severe exacerbation substudy were predominantly idiopathic 
bronchiectasis and non-smokers. Of 26 exacerbations, at diagnosis of exacerbation, sputum culture 
showed P. aeruginosa in 14 (54%), H. influenzae in 5 (19%), M. catarrhalis and S. aureus both in 2 
patients (8%) and E.coli, S. pneumoniae and S.maltophilia in 1 patient each. Compared to the overall 
study population, those with severe exacerbations had more severe disease in terms of worse 
radiological scoring, lower BMI, more frequent exacerbations and a higher bronchiectasis severity 
index score.  
 
 
 Exacerbation sub-
cohort 
Patients not 
included in the 
exacerbation 
cohort 
Overall cohort 
(sputum 
producers) 
p-value 
N 26 355 381  
Age (years) 68 (60-73) 67 (58-74) 67 (58-74) 0.8 
Gender  (% 
female) 
16 (61.5%) 209 (58.9%) 225 (59.1%) 0.8 
Aetiology 
Idiopathic 
Post-infective 
Others 
 
12 (46.2%) 
6 (23.1%) 
8 (30.8%) 
 
157 (44.2%) 
72 (20.3%) 
126 (34.5%) 
 
169 (44.4%) 
78 (20.5%) 
134 (35.2%) 
 
0.9 
0.7 
0.6 
Smoking 
(never) 
22 (84.6%) 217 (61.1%) 239 (62.7%) 0.02 
MRC dyspnoea 
score 
3 (2-4) 2(1-3) 2 (1-3) 0.4 
Reiff score 8 (5-10) 3 (2-6) 3 (2-6) <0.0001 
SGRQ total 
score 
58.3 (30.2-72.8) 45.6 (26.9-63.0) 46.1 (27.3-
63.2) 
0.1  
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FEV1% 
predicted 
65.7 (42.1-85.6) 72.2 (50.7-91.5) 71.4 (49.4-
90.9) 
0.2 
FVC % 
predicted 
75.6 (55.9-95.4) 83.9 (68.5-99.3) 83.2 (67.7-
98.7) 
0.2 
BMI 23.6 (20.7-26.4) 25.2 (22.3-28.9) 25.1 (22.2-
28.6) 
0.01 
Annual 
exacerbations  
3 (1-4) 1 (0-3) 1 (0-3) 0.005 
BSI total score 12 (7-16) 6 (4-10) 6 (4-11) <0.0001 
Table E6. Characteristics of patients included in the exacerbation substudy. Abbreviations 
MRC=medical research council, SGRQ= St.Georges Respiratory Questionnaire, FEV1= forced 
expiratory volume in 1 second, FVC= forced vital capacity, BMI= body mass index, BSI= 
bronchiectasis severity index. p-values refer to comparisons between exacerbation subcohort and 
those not included in the exacerbation subcohort.  
 
 
 
Figure E3. Correlation between 2 stable NE measurements while clinically stable before and after an 
exacerbation of bronchiectasis.  
 
Changes in neutrophil elastase at exacerbation and recovery 
As described in the main text, we observed increases in elastase between stability and the onset of 
exacerbations (p=0.002) and between exacerbation onset and recovery (p<0.0001). The median 
values are shown in figure E4.  
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 Figure E4. Changes in ABI-NE at exacerbation, recovery and longitudinal follow-up. Median with 
interquartile range is shown. Data are median with interquartile range.  
Page 42 of 42
